Financial Markets collage Northcote Internet Logo
transparent spacer
transparent spacer
 >   > 
transparent spacer
 
curve on page transparent spacer
Northcote Internet Ltd provide Investor Relations Webcasting. Click Here
 
transparent spacer transparent spacer transparent spacer transparent spacer
transparent spacer Home menu end curves
Newsletter
transparent spacer
transparent spacer About Us menu end curves
transparent spacer
transparent spacer Donations menu end curves
transparent spacer
transparent spacer Registrars menu end curves
transparent spacer
transparent spacer Spread Betting menu end curves
transparent spacer
transparent spacer Submit links menu end curves
transparent spacer
transparent spacer transparent spacer
transparent spacer transparent spacer transparent spacer
transparent spacer
transparent spacer
navigation curves Home navigation curves navigation curves By Index navigation curves navigation curves By Sector navigation curves navigation curves Alphabetically navigation curves navigation curves Search navigation curves navigation curves My Portfolio navigation curves
 >  > 
 
Follow northcote_b on Twitter
AstraZeneca
transparent spacer
transparent spacer
transparent spacer
Company Information
Address: Level 9 2 Kingdom Street
London
W2 6BD
Index: To continue showing the FTSE index and sector information we need a license from FTSE International Limited. Will anyone sponsor us to return this data to the site.
Tel: +44 (0)20 7604 8000 Sector:
Fax: +44 (0)20 7604 8270
E-Mail: IR@astrazeneca.com Epic:
Secretary: Adrian Kemp    
Registrar: Equiniti Ltd Updated: 9/02/2015

News from RSS Feed

Fri, 24 Apr 2015 07:00:00 +0100

AstraZeneca PLC first quarter results 2015

Pascal Soriot, Chief Executive Officer, commenting on the results, said: "Our encouraging performance in the quarter supports our full year guidance. Total Revenue grew by 1%, with the growth platforms representing 56%, after particularly strong results in Emerging Markets and with Brilinta/Brilique. Our co-commercialisation agreement for Movantik in the US was a good illustration of how we will bring important medicines to patients and externalisation value to our shareholders."

Company Overview

AstraZeneca is one of only a handful of pure-play biopharmaceutical companies to span the entire value chain of a medicine from discovery, early- and late-stage development to manufacturing and distribution, and the global commercialisation of primary care, specialty care-led and specialty care medicines that transform lives

 
Annual Reports
Description Report Date Published Current  
bullet point Annual Report 2014 in PDF 31/12/2014 5/02/2015 Yes  
bullet point Annual Report 2013 in PDF 31/12/2013 6/02/2014 No  
bullet point Annual Report 2012 in PDF 31/12/2012 31/01/2013 No  
bullet point Annual Report 2011 in PDF 31/12/2011 2/02/2012 No  
bullet point Annual Report 2010 in PDF 31/12/2010 27/01/2011 No  
bullet point Annual Report 2009 in PDF 31/12/2009 28/01/2010 No  
bullet point Annual Report 2008 in PDF 31/12/2008 29/01/2009 No  
bullet point Annual Report 2007 in PDF 31/12/2007 31/01/2008 No  
 
Interim Reports
Description Report Date Published Current  
bullet point Interim Results 2014 in PDF 30/06/2014 31/07/2014 Yes  
bullet point Interim Results 2013 in PDF 30/06/2013 1/08/2013 No  
bullet point Interim Results 2012 in PDF 30/06/2012 26/07/2012 No  
 
Other Links
Description
bullet point Home
bullet point Site Map
bullet point Investor Relations
bullet point Events Calendar
bullet point Results Index
bullet point Press Releases
bullet point Presentations
bullet point Contacts
bullet point RSS News Feed
       
Dividend History
Type Payment Date Dividend
Interim 15/09/2014 53.1 p
Interim 24/03/2014 116.8 p
Interim 16/09/2013 59.2 p
Interim 18/03/2013 120.5 p
Interim 10/09/2012 58.1 p
Interim 19/03/2012 123.6 p
Interim 12/09/2011 51.9 p
Interim 14/03/2011 116.7 p
Interim 13/09/2010 44.9 p
Interim 15/03/2010 105.4 p
Interim 14/09/2009 0.59 c USD
Interim 14/09/2009 27.8 p
Interim 14/09/2009 36 p
Interim 16/03/2009 104.8 p
Interim 15/09/2008 27.8 p
Interim 17/03/2008 67.7 p
Interim 17/09/2007 25.3 p
Interim 19/03/2007 63 p
Interim 18/09/2006 26.6 p
Interim 20/03/2006 51.8 p
Interim 19/09/2005 21.9 p
Interim 21/03/2005 34.3 p
Interim 20/09/2004 16 p
Interim 6/04/2004 29.4 p
Interim 6/10/2003 15.9 p
Interim 7/04/2003 28.5 p
Interim 7/10/2002 14.7 p
Interim 8/04/2002 33.2 p
Interim 5/10/2001 16.1 p
Interim 9/04/2001 32.1 p
Interim 23/10/2000 15.3 p
Interim 17/04/2000 29.1 p
Interim 25/10/1999 14.2 p

News from RSS Feed

Fri, 24 Apr 2015 07:00:00 +0100

AstraZeneca PLC first quarter results 2015

Pascal Soriot, Chief Executive Officer, commenting on the results, said: "Our encouraging performance in the quarter supports our full year guidance. Total Revenue grew by 1%, with the growth platforms representing 56%, after particularly strong results in Emerging Markets and with Brilinta/Brilique. Our co-commercialisation agreement for Movantik in the US was a good illustration of how we will bring important medicines to patients and externalisation value to our shareholders."
Fri, 24 Apr 2015 06:00:10 +0100

AstraZeneca enters strategic immuno-oncology collaboration with Celgene Corporation to develop PD-L1 inhibitor programme for patients with serious blood cancers

AstraZeneca and MedImmune, the Company’s global biologics research and development arm, today announced that they have entered into an exclusive collaboration agreement with Celgene Corporation, a global leader in haematological cancers, for the development and commercialisation of MEDI4736 across a range of blood cancers including non-Hodgkin’s lymphoma, myelodysplastic syndromes and multiple myeloma.
Fri, 24 Apr 2015 06:00:00 +0100

AstraZeneca and Innate Pharma announce global co-development and commercialisation collaboration for IPH2201 in immuno-oncology

AstraZeneca and MedImmune, the Company’s global biologics research and development arm, today announced that they have entered into a collaboration to accelerate and broaden the development of Innate Pharma SA’s proprietary anti-NKG2A antibody, IPH2201, including in combination with MEDI4736, an anti-PD-L1 immune checkpoint inhibitor developed by MedImmune. Currently in Phase II development, IPH2201 is a potential first-in-class humanised IgG4 antibody. NKG2A is a checkpoint receptor that inhibits the anti-cancer functions of Natural Killer (NK) and cytotoxic T-cells.
Fri, 17 Apr 2015 08:00:00 +0100

AstraZeneca announces updated progression free survival data for investigational non-small cell lung cancer medicine AZD9291

AstraZeneca today announced latest data from the ongoing AURA study of AZD9291 in patients with advanced epidermal growth factor receptor mutation positive (EGFRm) non-small cell lung cancer (NSCLC), who also have the T790M resistance mutation. The data demonstrated a median progression free survival (PFS) of 13.5 months (95% confidence interval (CI) 8.3 months to not calculable (NC)). These PFS findings relate to independently reviewed data from 63 patients with T790M tumours treated with AZD9291 at a dose of 80mg per day, and are based on only 38% of patients having tumour progression.
Fri, 17 Apr 2015 07:00:00 +0100

Selumetinib granted Orphan Drug Designation by US FDA for treatment of uveal melanoma

AstraZeneca today announced that the US Food and Drug Administration has granted Orphan Drug Designation for the MEK inhibitor selumetinib, for the treatment of uveal melanoma.
Thu, 16 Apr 2015 07:00:00 +0100

Medimmune and Immunocore announce new collaboration to conduct immuno-oncology combination trials in melanoma

AstraZeneca today announced that MedImmune, its global biologics research and development arm, has entered into a collaboration to conduct clinical trials in immuno-oncology with Immunocore Limited, a privately-held UK-based biotechnology company.
Wed, 15 Apr 2015 07:00:00 +0100

Tremelimumab granted Orphan Drug Designation by US FDA for treatment of malignant mesothelioma

AstraZeneca today announced that the US Food and Drug Administration has granted Orphan Drug Designation for the anti-CTLA-4 monoclonal antibody, tremelimumab, for the treatment of malignant mesothelioma.
Tue, 14 Apr 2015 18:30:00 +0100

FDA Advisory Committee reviews SAVOR outcomes study results for ONGLYZA® (saxagliptin) and KOMBIGLYZE® XR (saxagliptin and metformin HCI extended-release)

AstraZeneca today announced that the US Food and Drug Administration (FDA) Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) voted 13 to 1 (1 abstained; 15 total votes) that the results of the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus (SAVOR) study demonstrated that the use of saxagliptin in patients with type 2 diabetes has an acceptable cardiovascular risk profile. In addition, 14 out of 15 Committee members recommended that the FDA supplement the products’ labeling to add new safety information, with one vote to withdraw saxagliptin from the market.
Mon, 13 Apr 2015 12:40:24 +0100

AstraZeneca and PatientsLikeMe announce global research collaboration

In a major step forward to make patient-centric evidence a cornerstone of scientific discovery and development, AstraZeneca and PatientsLikeMe have signed a five-year agreement to provide access to PatientsLikeMe’s global network in support of AstraZeneca’s patient-driven research initiatives.
Mon, 13 Apr 2015 06:21:01 +0100

AstraZeneca to showcase strong oncology science at American Association for Cancer Research Annual Meeting 2015

AstraZeneca to showcase strong Oncology Science at American Association for Cancer Research Annual Meeting 2015. AstraZeneca will present new data at the American Association for Cancer Research (AACR) annual meeting in Philadelphia this weekend, demonstrating the strength and depth of its early stage oncology pipeline. 62 scientific abstracts from AstraZeneca and its global biologics research and development arm, MedImmune, will be featured at the meeting which runs from 18 to 22 April 2015. 15 of these will be oral presentations.
To continue showing the FTSE index and sector information we need a license from FTSE International Limited. Will anyone sponsor us to return this data to the site.


transparent spacer